Please login to the form below

Not currently logged in
Email:
Password:

Vertex and Tibotec reveal telaprevir results

Vertex Pharmaceuticals and Tibotec have revealed positive phase III results for telaprevir to treat chronic genotype 1 hepatitis C

Vertex Pharmaceuticals and Tibotec, an affiliate of Janssen Pharmaceutical Companies of Johnson & Johnson, have revealed positive phase III results for telaprevir to treat chronic genotype 1 hepatitis C.

Data showed that treatment with telaprevir, when combined with pegylated-interferon and ribavirin – the current standard of care treatment for hepatitis C – significantly improves cure rates for both previously untreated patients and patients whose prior treatment has failed, including those who showed no response to previous therapy.

In the REALIZE study, 83 per cent of patients whose prior treatment had failed, and classified as a relapser, achieved a cure when they took telaprevir on top of the standard treatment.

In the ADVANCE study, 75 per cent of previously untreated patients achieved a cure when they took telaprevir on top of the standard treatment.

The current standard of care treatment for hepatitis C is successful in only about 50 per cent of patients with genotype 1, leaving the other 50 per cent without a successful treatment outcome.

Graham Foster, professor of Hepatology, Queen Mary's, University of London, said: "Up until now genotype 1 hepatitis C patients have been very common and difficult to treat. The advent of a new standard of care with protease inhibitors provides fresh hope of a cure for people living with hepatitis C and significant advancements in treatment such as this will make a real difference in reducing the burden of hepatitis C."

23rd June 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
JPA Health

JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...

Latest intelligence

Are you ready for the digital health revolution?
In this edition of Delta magazine, we explore how rapid digitalization has transformed the care pathway and reveal how life science companies can succeed in the digital age....
#DemandDiversity: Can new medical publication guidelines help fix diversity in clinical trials?
Over the last 8 months, JAMA have been working on a new set of guidelines for research papers looking to publish with them, which is summarised in their latest editorial...
DATA shutterstock_1818502577-640.jpg
Empowering patients empowers results
Patient-centricity is key when it comes to creating a more flexible, efficient and modern process for clinical trials...

Infographics